Pharma Sector

After a week packed with major triggers like the Union Budget, the Indo-US trade deal, and the RBI policy, markets now turn to assessing real impact. The coming week will focus on how the trade deal affects exports, imports, currency risks, and overall market direction, along with key inflation and global data cues.

However, it is unclear whether the Hyderabad-based company will be Cobenfy's exclusive supplier.

Viyash manufactures active pharmaceutical ingredients (APIs) and drug formulations for the human health segment.

In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.

The partnership focuses on commercializing GLP-1 (glucagon-like peptide-1) products for diabetes treatment and chronic weight management in the Middle East.

This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.

The company plans to launch Durvalumab in 120 mg/2.4 mL and 500 mg/10 mL solutions in India, pending statutory approvals.

The said indication is for the use of durvalumab in combination with chemotherapy as a neoadjuvant treatment.

Earlier this year, Bajaj Healthcare secured formal CMO agreements with customers in the United Kingdom and the European Union to deliver 15 APIs.

Bayshore Pharmaceuticals is a 100% subsidiary of Unichem Laboratories' parent firm, Ipca Laboratories Ltd.